Details of the Drug

General Information of Drug (ID: DMPFN6Y)

Drug Name
Olanzapine
Synonyms
Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 312.4
Topological Polar Surface Area (xlogp) 2.9
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 333 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 150 mcg/L [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
60% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The clearance of drug is 29.4 L/h [6]
Elimination
Olanzapine is mainly eliminated through metabolism and hence, only 7% of the eliminated drug can be found as the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 21 - 54 hours [3]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.68586 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 1000 L [3]
Water Solubility
The ability of drug to dissolve in water is measured as 0.01 mg/mL [4]
Chemical Identifiers
Formula
C17H20N4S
IUPAC Name
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
Canonical SMILES
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
InChIKey
KVWDHTXUZHCGIO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135398745
ChEBI ID
CHEBI:7735
CAS Number
132539-06-1
DrugBank ID
DB00334
TTD ID
D0V4QS
VARIDT ID
DR00462
INTEDE ID
DR1186
ACDINA ID
D00484

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Olanzapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Olanzapine and Quetiapine. Schizophrenia [6A20] [48]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Olanzapine and Mesoridazine. Schizophrenia [6A20] [48]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Olanzapine and Thioridazine. Schizophrenia [6A20] [48]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Olanzapine and Aripiprazole. Schizophrenia [6A20] [48]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Olanzapine and Iloperidone. Schizophrenia [6A20] [48]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Olanzapine and Paliperidone. Schizophrenia [6A20] [48]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Olanzapine and Loxapine. Schizophrenia [6A20] [48]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Olanzapine and Molindone. Schizophrenia [6A20] [48]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Olanzapine and Chlorpromazine. Schizophrenia [6A20] [48]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Olanzapine and Thiothixene. Schizophrenia [6A20] [48]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Olanzapine and Trifluoperazine. Schizophrenia [6A20] [48]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Olanzapine and Risperidone. Schizophrenia [6A20] [48]
Amisulpride DMSJVAM Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Amisulpride. Schizophrenia [6A20] [49]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Olanzapine and Asenapine. Schizophrenia [6A20] [48]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Olanzapine and Pimozide. Schizophrenia [6A20] [48]
⏷ Show the Full List of 15 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Olanzapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ivosidenib. Acute myeloid leukaemia [2A60] [49]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Midostaurin. Acute myeloid leukaemia [2A60] [49]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Idarubicin. Acute myeloid leukaemia [2A60] [49]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Daunorubicin. Acute myeloid leukaemia [2A60] [49]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Arn-509. Acute myeloid leukaemia [2A60] [49]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Oliceridine. Acute pain [MG31] [49]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Olanzapine and Scopolamine. Addictive disorder [6C50-6C5Z] [48]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Olanzapine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [50]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Olanzapine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [50]
Tacrine DM51FY6 Moderate Antagonize the effect of Olanzapine when combined with Tacrine. Alzheimer disease [8A20] [51]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Olanzapine and Memantine. Alzheimer disease [8A20] [48]
Rivastigmine DMG629M Moderate Antagonize the effect of Olanzapine when combined with Rivastigmine. Alzheimer disease [8A20] [51]
Donepezil DMIYG7Z Moderate Antagonize the effect of Olanzapine when combined with Donepezil. Alzheimer disease [8A20] [51]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Olanzapine and Metronidazole. Amoebiasis [1A36] [49]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Olanzapine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [52]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Olanzapine and Trimethaphan. Aneurysm/dissection [BD50] [53]
Bepridil DM0RKS4 Moderate Additive hypotensive effects by the combination of Olanzapine and Bepridil. Angina pectoris [BA40] [52]
Dronedarone DMA8FS5 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Dronedarone. Angina pectoris [BA40] [49]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Olanzapine and Amyl nitrite. Angina pectoris [BA40] [52]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Olanzapine and Nifedipine. Angina pectoris [BA40] [52]
Bedaquiline DM3906J Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [49]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Olanzapine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [48]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Cilostazol. Arterial occlusive disease [BD40] [49]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Voriconazole. Aspergillosis [1F20] [49]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Posaconazole. Aspergillosis [1F20] [49]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Levalbuterol. Asthma [CA23] [49]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Terbutaline. Asthma [CA23] [49]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Pirbuterol. Asthma [CA23] [49]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Salbutamol. Asthma [CA23] [49]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [49]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Olanzapine and Desipramine. Attention deficit hyperactivity disorder [6A05] [48]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Olanzapine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [54]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ofloxacin. Bacterial infection [1A00-1C4Z] [49]
Ciprofloxacin XR DM2NLS9 Minor Decreased metabolism of Olanzapine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [54]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Clarithromycin. Bacterial infection [1A00-1C4Z] [49]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Olanzapine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [55]
Sparfloxacin DMB4HCT Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [49]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [49]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Norfloxacin. Bacterial infection [1A00-1C4Z] [49]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [49]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Telithromycin. Bacterial infection [1A00-1C4Z] [49]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Retigabine. Behcet disease [4A62] [49]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Olanzapine and Cariprazine. Bipolar disorder [6A60] [48]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Eribulin. Breast cancer [2C60-2C6Y] [49]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Lapatinib. Breast cancer [2C60-2C6Y] [49]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Tamoxifen. Breast cancer [2C60-2C6Y] [49]
Toremifene DMQYUWG Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Toremifene. Breast cancer [2C60-2C6Y] [49]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Bosutinib. Breast cancer [2C60-2C6Y] [49]
Sotalol DML60TN Moderate Additive hypotensive effects by the combination of Olanzapine and Sotalol. Cardiac arrhythmia [BC9Z] [52]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Olanzapine when combined with Acetylcholine. Cataract [9B10] [56]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [49]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Olanzapine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [57]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [49]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [49]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Olanzapine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [57]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [49]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [49]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [49]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Olanzapine and Dihydrocodeine. Chronic pain [MG30] [58]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Oxaliplatin. Colorectal cancer [2B91] [49]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Isoproterenol. Conduction disorder [BC63] [49]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Olanzapine and Olopatadine. Conjunctiva disorder [9A60] [59]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Halothane. Corneal disease [9A76-9A78] [49]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Propofol. Corneal disease [9A76-9A78] [60]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Sevoflurane. Corneal disease [9A76-9A78] [49]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Olanzapine and Alfentanil. Corneal disease [9A76-9A78] [61]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Olanzapine and Remifentanil. Corneal disease [9A76-9A78] [61]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Probucol. Coronary atherosclerosis [BA80] [49]
Nimodipine DMQ0RKZ Moderate Additive hypotensive effects by the combination of Olanzapine and Nimodipine. Coronary vasospastic disease [BA85] [52]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Clofazimine. Crohn disease [DD70] [49]
Pasireotide DMHM7JS Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Pasireotide. Cushing syndrome [5A70] [49]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Olanzapine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [54]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Olanzapine and Ethanol. Cystitis [GC00] [59]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Olanzapine and Cyclandelate. Dementia [6D80-6D8Z] [52]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Olanzapine and Cyclobenzaprine. Depression [6A70-6A7Z] [48]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Olanzapine and Imipramine. Depression [6A70-6A7Z] [48]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Olanzapine and Nortriptyline. Depression [6A70-6A7Z] [48]
Escitalopram DMFK9HG Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Escitalopram. Depression [6A70-6A7Z] [49]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Olanzapine and OPC-34712. Depression [6A70-6A7Z] [48]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Olanzapine and Clomipramine. Depression [6A70-6A7Z] [48]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Trazodone. Depression [6A70-6A7Z] [49]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Olanzapine and Amoxapine. Depression [6A70-6A7Z] [48]
Protriptyline DMNHTZI Moderate Additive anticholinergic effects by the combination of Olanzapine and Protriptyline. Depression [6A70-6A7Z] [48]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Olanzapine and Doxepin. Depression [6A70-6A7Z] [48]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Olanzapine and Maprotiline. Depression [6A70-6A7Z] [48]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Olanzapine and Nitroglycerin. Diabetic foot ulcer [BD54] [52]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Olanzapine and Hyoscyamine. Digestive system disease [DE2Z] [48]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Olanzapine and Mepenzolate. Digestive system disease [DE2Z] [48]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Olanzapine and Oxybutynine. Discovery agent [N.A.] [48]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Olanzapine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [62]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Olanzapine and Meclizine. Dizziness and giddiness [MB48] [48]
Trihexyphenidyl DMB19L8 Moderate Antagonize the effect of Olanzapine when combined with Trihexyphenidyl. Dystonic disorder [8A02] [63]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Olanzapine and Deutetrabenazine. Dystonic disorder [8A02] [64]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ingrezza. Dystonic disorder [8A02] [49]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Olanzapine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [65]
Carbamazepine DMZOLBI Moderate Increased metabolism of Olanzapine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Olanzapine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [63]
Timolol DM3NXRU Moderate Additive hypotensive effects by the combination of Olanzapine and Timolol. Essential hypertension [BA00] [52]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Olanzapine and Guanabenz. Essential hypertension [BA00] [52]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Olanzapine and Ethacrynic acid. Essential hypertension [BA00] [53]
Bendroflumethiazide DM7EVLC Moderate Additive hypotensive effects by the combination of Olanzapine and Bendroflumethiazide. Essential hypertension [BA00] [52]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Olanzapine and Phenoxybenzamine. Essential hypertension [BA00] [52]
Guanethidine DM9NSWT Moderate Additive hypotensive effects by the combination of Olanzapine and Guanethidine. Essential hypertension [BA00] [52]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Olanzapine and Nicardipine. Essential hypertension [BA00] [52]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Olanzapine and Mecamylamine. Essential hypertension [BA00] [52]
Benzthiazide DMQWZ0H Moderate Additive hypotensive effects by the combination of Olanzapine and Benzthiazide. Essential hypertension [BA00] [52]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Olanzapine and Nadolol. Essential hypertension [BA00] [52]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Olanzapine and Solifenacin. Functional bladder disorder [GC50] [48]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Olanzapine and Tolterodine. Functional bladder disorder [GC50] [48]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Pentamidine. Fungal infection [1F29-1F2F] [49]
Terbinafine DMI6HUW Moderate Decreased metabolism of Olanzapine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [67]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ketoconazole. Fungal infection [1F29-1F2F] [49]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Olanzapine and Phentolamine. Gangrene [MC85] [52]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Olanzapine and Propantheline. Gastric ulcer [DA60] [48]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [49]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Olanzapine when combined with Isoflurophate. Glaucoma [9C61] [56]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Olanzapine and Carteolol. Glaucoma [9C61] [52]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Olanzapine and Brimonidine. Glaucoma [9C61] [68]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Olanzapine when combined with Pilocarpine. Glaucoma [9C61] [56]
Spironolactone DM2AQ5N Moderate Additive hypotensive effects by the combination of Olanzapine and Spironolactone. Heart failure [BD10-BD1Z] [52]
Triamterene DM2HU9I Moderate Additive hypotensive effects by the combination of Olanzapine and Triamterene. Heart failure [BD10-BD1Z] [52]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Olanzapine and Prazosin. Heart failure [BD10-BD1Z] [52]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Olanzapine and Eplerenone. Heart failure [BD10-BD1Z] [52]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Olanzapine and Chlorothiazide. Heart failure [BD10-BD1Z] [52]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Olanzapine and Furosemide. Heart failure [BD10-BD1Z] [52]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Olanzapine and Amiloride. Heart failure [BD10-BD1Z] [52]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Olanzapine and Bumetanide. Heart failure [BD10-BD1Z] [52]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Olanzapine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [52]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Efavirenz DMC0GSJ Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [49]
Saquinavir DMG814N Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [49]
Ritonavir DMU764S Moderate Increased metabolism of Olanzapine caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Olanzapine and Isosorbide mononitrate. Hydrocephalus [8D64] [52]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Olanzapine caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [66]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Olanzapine and Eprosartan. Hypertension [BA00-BA04] [52]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Olanzapine and Acebutolol. Hypertension [BA00-BA04] [52]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Olanzapine and Moexipril. Hypertension [BA00-BA04] [52]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Olanzapine and Bisoprolol. Hypertension [BA00-BA04] [52]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Olanzapine and Captopril. Hypertension [BA00-BA04] [52]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Olanzapine and Penbutolol. Hypertension [BA00-BA04] [52]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Olanzapine and Trandolapril. Hypertension [BA00-BA04] [52]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Olanzapine and Methyldopa. Hypertension [BA00-BA04] [52]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Olanzapine and Clonidine. Hypertension [BA00-BA04] [52]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Olanzapine and Losartan. Hypertension [BA00-BA04] [52]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Olanzapine and Nebivolol. Hypertension [BA00-BA04] [52]
Nisoldipine DM7ISKJ Moderate Additive hypotensive effects by the combination of Olanzapine and Nisoldipine. Hypertension [BA00-BA04] [52]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Olanzapine and Levamlodipine. Hypertension [BA00-BA04] [52]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Olanzapine and Fosinopril. Hypertension [BA00-BA04] [52]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Olanzapine and Doxazosin. Hypertension [BA00-BA04] [52]
Minoxidil DMA2Z4F Moderate Additive hypotensive effects by the combination of Olanzapine and Minoxidil. Hypertension [BA00-BA04] [52]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Olanzapine and Verapamil. Hypertension [BA00-BA04] [52]
Diltiazem DMAI7ZV Moderate Additive hypotensive effects by the combination of Olanzapine and Diltiazem. Hypertension [BA00-BA04] [52]
Amlodipine DMBDAZV Moderate Additive hypotensive effects by the combination of Olanzapine and Amlodipine. Hypertension [BA00-BA04] [52]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Olanzapine and TAK-491. Hypertension [BA00-BA04] [52]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Olanzapine and Pindolol. Hypertension [BA00-BA04] [52]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Olanzapine and Fenoldopam. Hypertension [BA00-BA04] [52]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Olanzapine and Indapamide. Hypertension [BA00-BA04] [52]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Olanzapine and Trichlormethiazide. Hypertension [BA00-BA04] [52]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Olanzapine and Labetalol. Hypertension [BA00-BA04] [52]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Olanzapine and Diazoxide. Hypertension [BA00-BA04] [52]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Olanzapine and Enalapril. Hypertension [BA00-BA04] [52]
Atenolol DMNKG1Z Moderate Additive hypotensive effects by the combination of Olanzapine and Atenolol. Hypertension [BA00-BA04] [52]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Olanzapine and Perindopril. Hypertension [BA00-BA04] [52]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Olanzapine and Felodipine. Hypertension [BA00-BA04] [52]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Olanzapine and Quinapril. Hypertension [BA00-BA04] [52]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Olanzapine and Deserpidine. Hypertension [BA00-BA04] [52]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Olanzapine and Telmisartan. Hypertension [BA00-BA04] [52]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Olanzapine and Irbesartan. Hypertension [BA00-BA04] [52]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Olanzapine and Hydralazine. Hypertension [BA00-BA04] [52]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Olanzapine and Hydrochlorothiazide. Hypertension [BA00-BA04] [52]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Olanzapine and Clevidipine butyrate. Hypertension [BA00-BA04] [52]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Olanzapine and Potassium chloride. Hypo-kalaemia [5C77] [70]
Givosiran DM5PFIJ Moderate Decreased metabolism of Olanzapine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [54]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Olanzapine and Amantadine. Influenza [1E30-1E32] [71]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Olanzapine and Propiomazine. Insomnia [7A00-7A0Z] [48]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Olanzapine and ITI-007. Insomnia [7A00-7A0Z] [48]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Olanzapine and Polyethylene glycol. Irritable bowel syndrome [DD91] [72]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Olanzapine and Clidinium. Irritable bowel syndrome [DD91] [48]
Physostigmine DM2N0TO Moderate Antagonize the effect of Olanzapine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [51]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Olanzapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [66]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Olanzapine and Porfimer Sodium. Lung cancer [2C25] [73]
Ceritinib DMB920Z Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ceritinib. Lung cancer [2C25] [49]
Osimertinib DMRJLAT Moderate Increased metabolism of Olanzapine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [74]
Capmatinib DMYCXKL Moderate Decreased metabolism of Olanzapine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [54]
Lumefantrine DM29GAD Moderate Decreased metabolism of Olanzapine caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [49]
Halofantrine DMOMK1V Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Halofantrine. Malaria [1F40-1F45] [49]
Chloroquine DMSI5CB Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Chloroquine. Malaria [1F40-1F45] [49]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Hydroxychloroquine. Malaria [1F40-1F45] [49]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Quinine. Malaria [1F40-1F45] [49]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Primaquine. Malaria [1F40-1F45] [49]
Mefloquine DMWT905 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Mefloquine. Malaria [1F40-1F45] [49]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [49]
Arsenic trioxide DM61TA4 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [49]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Olanzapine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [54]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and LGX818. Melanoma [2C30] [49]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Olanzapine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [75]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Olanzapine and Propranolol. Migraine [8A80] [52]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Olanzapine and Lasmiditan. Migraine [8A80] [76]
Exjade DMHPRWG Moderate Decreased metabolism of Olanzapine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [54]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Olanzapine and Flibanserin. Mood disorder [6A60-6E23] [77]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Olanzapine and Doxylamine. Morning sickness disorder [SC00] [48]
Panobinostat DM58WKG Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Panobinostat. Multiple myeloma [2A83] [49]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Olanzapine and Thalidomide. Multiple myeloma [2A83] [78]
Siponimod DM2R86O Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Siponimod. Multiple sclerosis [8A40] [49]
Fingolimod DM5JVAN Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Fingolimod. Multiple sclerosis [8A40] [49]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Olanzapine and Ozanimod. Multiple sclerosis [8A40] [49]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Romidepsin. Mycosis fungoides [2B01] [49]
Nilotinib DM7HXWT Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Nilotinib. Myeloproliferative neoplasm [2A20] [49]
Imatinib DM7RJXL Moderate Decreased metabolism of Olanzapine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [79]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Dasatinib. Myeloproliferative neoplasm [2A20] [49]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Olanzapine and Phenindamine. Nasopharyngitis [CA00] [48]
Droperidol DM0DXA8 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Droperidol. Nausea/vomiting [MD90] [49]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Olanzapine and Dimenhydrinate. Nausea/vomiting [MD90] [48]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Olanzapine and Prochlorperazine. Nausea/vomiting [MD90] [48]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Olanzapine and Promethazine. Nausea/vomiting [MD90] [48]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Olanzapine and Cyclizine. Nausea/vomiting [MD90] [48]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Palonosetron. Nausea/vomiting [MD90] [49]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Olanzapine and Metoclopramide. Nausea/vomiting [MD90] [80]
Dolasetron DMMG26Z Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Dolasetron. Nausea/vomiting [MD90] [49]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ondansetron. Nausea/vomiting [MD90] [49]
Thiethylperazine DMU3IET Moderate Additive anticholinergic effects by the combination of Olanzapine and Thiethylperazine. Nausea/vomiting [MD90] [48]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Olanzapine and Bupropion. Nicotine use disorder [6C4A] [81]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Olanzapine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [82]
Metolazone DMB39LO Moderate Additive hypotensive effects by the combination of Olanzapine and Metolazone. Oedema [MG29] [52]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Olanzapine and Polythiazide. Oedema [MG29] [52]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Olanzapine and Levomethadyl Acetate. Opioid use disorder [6C43] [58]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Olanzapine and Lofexidine. Opioid use disorder [6C43] [52]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Olanzapine and Apraclonidine. Optic nerve disorder [9C40] [68]
Olaparib DM8QB1D Moderate Increased metabolism of Olanzapine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [49]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Olanzapine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [54]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Olanzapine and Pentazocine. Pain [MG30-MG3Z] [61]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Olanzapine and Dextropropoxyphene. Pain [MG30-MG3Z] [83]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Olanzapine and Butorphanol. Pain [MG30-MG3Z] [61]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Olanzapine and Oxymorphone. Pain [MG30-MG3Z] [61]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Olanzapine and Levorphanol. Pain [MG30-MG3Z] [61]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Olanzapine and Dezocine. Pain [MG30-MG3Z] [61]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Olanzapine and Flavoxate. Pain [MG30-MG3Z] [48]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Olanzapine and Nalbuphine. Pain [MG30-MG3Z] [61]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Olanzapine and Buprenorphine. Pain [MG30-MG3Z] [84]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Olanzapine and Meperidine. Pain [MG30-MG3Z] [61]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Olanzapine and Oxycodone. Pain [MG30-MG3Z] [61]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Triclabendazole. Parasitic worm infestation [1F90] [49]
Pergolide DM14MAE Moderate Antagonize the effect of Olanzapine when combined with Pergolide. Parkinsonism [8A00] [85]
Opicapone DM1BKA6 Moderate Antagonize the effect of Olanzapine when combined with Opicapone. Parkinsonism [8A00] [85]
Biperiden DME78OA Moderate Antagonize the effect of Olanzapine when combined with Biperiden. Parkinsonism [8A00] [63]
Procyclidine DMHFJDT Moderate Antagonize the effect of Olanzapine when combined with Procyclidine. Parkinsonism [8A00] [63]
Entacapone DMLBVKQ Moderate Antagonize the effect of Olanzapine when combined with Entacapone. Parkinsonism [8A00] [85]
Levodopa DMN3E57 Moderate Antagonize the effect of Olanzapine when combined with Levodopa. Parkinsonism [8A00] [85]
Pramipexole DMNMW9R Moderate Additive hypotensive effects by the combination of Olanzapine and Pramipexole. Parkinsonism [8A00] [85]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Pimavanserin. Parkinsonism [8A00] [49]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Olanzapine when combined with Bromocriptine. Parkinsonism [8A00] [85]
Apomorphine DMX38HQ Moderate Antagonize the effect of Olanzapine when combined with Apomorphine. Parkinsonism [8A00] [86]
Abametapir DM2RX0I Moderate Decreased metabolism of Olanzapine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [87]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Olanzapine and Lindane. Pediculosis [1G00] [88]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Olanzapine and Methylscopolamine. Peptic ulcer [DA61] [48]
Macimorelin DMQYJIR Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Macimorelin. Pituitary gland disorder [5A60-5A61] [49]
Lefamulin DME6G97 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Lefamulin. Pneumonia [CA40] [49]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Ritodrine. Preterm labour/delivery [JB00] [49]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Degarelix. Prostate cancer [2C82] [49]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Olanzapine and ABIRATERONE. Prostate cancer [2C82] [49]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Nilutamide. Prostate cancer [2C82] [49]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Enzalutamide. Prostate cancer [2C82] [49]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Flutamide. Prostate cancer [2C82] [49]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Relugolix. Prostate cancer [2C82] [49]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Bicalutamide. Prostate cancer [2C82] [49]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Olanzapine and Terazosin. Prostate hyperplasia [GA90] [52]
Alfuzosin DMZVMKF Moderate Additive hypotensive effects by the combination of Olanzapine and Alfuzosin. Prostate hyperplasia [GA90] [52]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Olanzapine and Levomepromazine. Psychotic disorder [6A20-6A25] [48]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Olanzapine and Triflupromazine. Psychotic disorder [6A20-6A25] [48]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Olanzapine and Tolazoline. Pulmonary hypertension [BB01] [52]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Sorafenib. Renal cell carcinoma [2C90] [49]
Gatifloxacin DMSL679 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [49]
Neupro DMHEAB1 Moderate Antagonize the effect of Olanzapine when combined with Neupro. Restless legs syndrome [7A80] [85]
Celecoxib DM6LOQU Moderate Decreased metabolism of Olanzapine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [89]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Olanzapine and Cyproheptadine. Rheumatoid arthritis [FA20] [48]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Olanzapine and Fentanyl. Sensation disturbance [MB40] [61]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Olanzapine and Sufentanil. Sensation disturbance [MB40] [61]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Vardenafil. Sexual dysfunction [HA00-HA01] [49]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [49]
Vandetanib DMRICNP Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [49]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [49]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [49]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Pitolisant. Somnolence [MG42] [49]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [49]
Cabozantinib DMIYDT4 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Cabozantinib. Thyroid cancer [2D10] [49]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Olanzapine and Papaverine. Tonus and reflex abnormality [MB47] [52]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Olanzapine and Tizanidine. Tonus and reflex abnormality [MB47] [90]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Olanzapine and Atropine. Unspecific substance harmful effect [NE6Z] [48]
Enoxacin DMYTE6L Minor Decreased metabolism of Olanzapine caused by Enoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [54]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Astemizole. Vasomotor/allergic rhinitis [CA08] [49]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Olanzapine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [48]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Olanzapine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [48]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Olanzapine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [48]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Olanzapine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [48]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Olanzapine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [50]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Olanzapine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [48]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Olanzapine and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [48]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Olanzapine and Cetirizine. Vasomotor/allergic rhinitis [CA08] [91]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Olanzapine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [48]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Olanzapine and Azatadine. Vasomotor/allergic rhinitis [CA08] [48]
Procainamide DMNMXR8 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Procainamide. Ventricular tachyarrhythmia [BC71] [49]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Propafenone. Ventricular tachyarrhythmia [BC71] [49]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Flecainide. Ventricular tachyarrhythmia [BC71] [49]
Amiodarone DMUTEX3 Moderate Increased risk of prolong QT interval by the combination of Olanzapine and Amiodarone. Ventricular tachyarrhythmia [BC71] [49]
⏷ Show the Full List of 305 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aspartame E00402 134601 Flavoring agent
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben E00543 23663626 Antimicrobial preservative
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Magnesium sulfate E00281 24083 Vaccine adjuvant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 36 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Olanzapine 10 mg tablet 10 mg Disintegrating Oral Tablet Oral
Olanzapine 15 mg tablet 15 mg Disintegrating Oral Tablet Oral
Olanzapine 20 mg tablet 20 mg Disintegrating Oral Tablet Oral
Olanzapine 5 mg tablet 5 mg Disintegrating Oral Tablet Oral
Olanzapine 20 mg tablet 20 mg Oral Tablet Oral
Olanzapine 15 mg tablet 15 mg Oral Tablet Oral
Olanzapine 10 mg tablet 10 mg Disintegrating Tablet Oral
Olanzapine 15 mg tablet 15 mg Disintegrating Tablet Oral
Olanzapine 20 mg tablet 20 mg Disintegrating Tablet Oral
Olanzapine 5 mg tablet 5 mg Disintegrating Tablet Oral
Olanzapine 10 mg tablet 10 mg Oral Tablet Oral
Olanzapine 2.5 mg tablet 2.5 mg Oral Tablet Oral
Olanzapine 5 mg tablet 5 mg Oral Tablet Oral
Olanzapine 7.5 mg tablet 7.5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 47).
2 Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.
3 Olanzapine .
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
9 [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
10 Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003 Mar;28(2):99-112.
11 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
12 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
13 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
14 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
15 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
16 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
19 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
20 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
25 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
27 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
28 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
29 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
30 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
31 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
32 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
33 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
34 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
35 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
36 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
37 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
38 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
39 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
40 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
41 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
42 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
43 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
44 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
45 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
46 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
47 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
48 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
49 Cerner Multum, Inc. "Australian Product Information.".
50 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
51 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
52 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
53 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
54 Albers LJ, Ozdemir V, Marder SR, et al. "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy." J Clin Psychopharmacol 25 (2005): 170-174. [PMID: 15738749]
55 Canadian Pharmacists Association.
56 Multum Information Services, Inc. Expert Review Panel.
57 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
58 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
59 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
60 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
61 Cerner Multum, Inc. "Canadian Product Information.".
62 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
63 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
64 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
65 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
66 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
67 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
68 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
69 Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW "Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers." J Clin Psychopharmacol 22 (2002): 366-370. [PMID: 12172335]
70 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
71 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
72 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
73 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
74 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
76 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
77 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
78 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
79 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
80 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
81 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
82 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
83 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
84 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
85 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
86 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
87 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
88 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
89 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
90 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
91 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.